Antimicrobial Activities of Fidaxomicin
Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001—1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC 90 ) of 0.5 μg/m...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2012-08, Vol.55 (suppl_2), p.S143-S148 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S148 |
|---|---|
| container_issue | suppl_2 |
| container_start_page | S143 |
| container_title | Clinical infectious diseases |
| container_volume | 55 |
| creator | Goldstein, Ellie J. C. Babakhani, Farah Citron, Diane M. |
| description | Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001—1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC 90 ) of 0.5 μg/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 μg/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 μg/mL and an MIC 90 of 8 μg/mL. Changes in inoculum size (10 2 —10 5 colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast. |
| doi_str_mv | 10.1093/cid/cis339 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3388021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23249805</jstor_id><sourcerecordid>23249805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-92717cb897dc46aa41412876ebfca4e46237cc448bb58de7dca5532e9ac5de773</originalsourceid><addsrcrecordid>eNqFkc9LwzAUx4Mobk4v3pWBB0Wo5uVHm16EMZwKAy96DmmaakbbzKYd-t-b0Tl_XDyEl7zvhy9574vQMeArwCm91jYPx1Oa7qAhcJpEMU9hN9wxFxETVAzQgfcLjAEE5vtoQEjCiYjpEJ1P6tZWVjcus6ocT3RrV7a1xo9dMZ7ZXL27oNr6EO0VqvTmaFNH6Hl2-zS9j-aPdw_TyTzSLIY2SkkCic5EmuShoRQDBkQksckKrZhhMaGJ1oyJLOMiN4FSnFNiUqV5eCZ0hG5632WXVSbXpm4bVcplYyvVfEinrPyt1PZVvriVpFQITCAYXGwMGvfWGd_KynptylLVxnVeAiEANI4F_R_FhAEGynhAz_6gC9c1ddjEmorD2KlYU5c9FdbpfWOK7b8By3VUMkQl-6gCfPpz0i36lU0ATnpg4VvXfOuUsDTESD8BGqyYhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026927985</pqid></control><display><type>article</type><title>Antimicrobial Activities of Fidaxomicin</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Goldstein, Ellie J. C. ; Babakhani, Farah ; Citron, Diane M.</creator><creatorcontrib>Goldstein, Ellie J. C. ; Babakhani, Farah ; Citron, Diane M.</creatorcontrib><description>Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001—1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC 90 ) of 0.5 μg/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 μg/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 μg/mL and an MIC 90 of 8 μg/mL. Changes in inoculum size (10 2 —10 5 colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cis339</identifier><identifier>PMID: 22752863</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Aminoglycosides - pharmacology ; Anaerobic bacteria ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Antimicrobials ; Bacteria ; Clinical trials ; Clinical Trials as Topic ; Clostridium difficile ; Clostridium difficile - drug effects ; Clostridium difficile - isolation & purification ; Clostridium Infections - microbiology ; Drug Evaluation, Preclinical ; Drug Resistance, Bacterial ; Feces - microbiology ; Genetic mutation ; Humans ; Hydrogen-Ion Concentration ; Infections ; Inoculum ; Medical treatment ; Metabolites ; Microbial Sensitivity Tests ; Pharmaceutical preparations ; Recurrence ; RNA ; Supplement ; Vancomycin - pharmacology ; Yeast</subject><ispartof>Clinical infectious diseases, 2012-08, Vol.55 (suppl_2), p.S143-S148</ispartof><rights>Copyright University of Chicago, acting through its Press Aug 1, 2012</rights><rights>The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please email: journals.permissions@oup.com. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-92717cb897dc46aa41412876ebfca4e46237cc448bb58de7dca5532e9ac5de773</citedby><cites>FETCH-LOGICAL-c461t-92717cb897dc46aa41412876ebfca4e46237cc448bb58de7dca5532e9ac5de773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23249805$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23249805$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,780,784,803,885,27923,27924,58016,58249</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22752863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldstein, Ellie J. C.</creatorcontrib><creatorcontrib>Babakhani, Farah</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><title>Antimicrobial Activities of Fidaxomicin</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001—1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC 90 ) of 0.5 μg/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 μg/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 μg/mL and an MIC 90 of 8 μg/mL. Changes in inoculum size (10 2 —10 5 colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast.</description><subject>Aminoglycosides - pharmacology</subject><subject>Anaerobic bacteria</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Antimicrobials</subject><subject>Bacteria</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Clostridium difficile</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - isolation & purification</subject><subject>Clostridium Infections - microbiology</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Resistance, Bacterial</subject><subject>Feces - microbiology</subject><subject>Genetic mutation</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Infections</subject><subject>Inoculum</subject><subject>Medical treatment</subject><subject>Metabolites</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmaceutical preparations</subject><subject>Recurrence</subject><subject>RNA</subject><subject>Supplement</subject><subject>Vancomycin - pharmacology</subject><subject>Yeast</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9LwzAUx4Mobk4v3pWBB0Wo5uVHm16EMZwKAy96DmmaakbbzKYd-t-b0Tl_XDyEl7zvhy9574vQMeArwCm91jYPx1Oa7qAhcJpEMU9hN9wxFxETVAzQgfcLjAEE5vtoQEjCiYjpEJ1P6tZWVjcus6ocT3RrV7a1xo9dMZ7ZXL27oNr6EO0VqvTmaFNH6Hl2-zS9j-aPdw_TyTzSLIY2SkkCic5EmuShoRQDBkQksckKrZhhMaGJ1oyJLOMiN4FSnFNiUqV5eCZ0hG5632WXVSbXpm4bVcplYyvVfEinrPyt1PZVvriVpFQITCAYXGwMGvfWGd_KynptylLVxnVeAiEANI4F_R_FhAEGynhAz_6gC9c1ddjEmorD2KlYU5c9FdbpfWOK7b8By3VUMkQl-6gCfPpz0i36lU0ATnpg4VvXfOuUsDTESD8BGqyYhw</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Goldstein, Ellie J. C.</creator><creator>Babakhani, Farah</creator><creator>Citron, Diane M.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120801</creationdate><title>Antimicrobial Activities of Fidaxomicin</title><author>Goldstein, Ellie J. C. ; Babakhani, Farah ; Citron, Diane M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-92717cb897dc46aa41412876ebfca4e46237cc448bb58de7dca5532e9ac5de773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aminoglycosides - pharmacology</topic><topic>Anaerobic bacteria</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Antimicrobials</topic><topic>Bacteria</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Clostridium difficile</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - isolation & purification</topic><topic>Clostridium Infections - microbiology</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Resistance, Bacterial</topic><topic>Feces - microbiology</topic><topic>Genetic mutation</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Infections</topic><topic>Inoculum</topic><topic>Medical treatment</topic><topic>Metabolites</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmaceutical preparations</topic><topic>Recurrence</topic><topic>RNA</topic><topic>Supplement</topic><topic>Vancomycin - pharmacology</topic><topic>Yeast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldstein, Ellie J. C.</creatorcontrib><creatorcontrib>Babakhani, Farah</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldstein, Ellie J. C.</au><au>Babakhani, Farah</au><au>Citron, Diane M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial Activities of Fidaxomicin</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>55</volume><issue>suppl_2</issue><spage>S143</spage><epage>S148</epage><pages>S143-S148</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001—1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC 90 ) of 0.5 μg/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 μg/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 μg/mL and an MIC 90 of 8 μg/mL. Changes in inoculum size (10 2 —10 5 colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>22752863</pmid><doi>10.1093/cid/cis339</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2012-08, Vol.55 (suppl_2), p.S143-S148 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3388021 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Aminoglycosides - pharmacology Anaerobic bacteria Anti-Bacterial Agents - pharmacology Antibiotics Antimicrobials Bacteria Clinical trials Clinical Trials as Topic Clostridium difficile Clostridium difficile - drug effects Clostridium difficile - isolation & purification Clostridium Infections - microbiology Drug Evaluation, Preclinical Drug Resistance, Bacterial Feces - microbiology Genetic mutation Humans Hydrogen-Ion Concentration Infections Inoculum Medical treatment Metabolites Microbial Sensitivity Tests Pharmaceutical preparations Recurrence RNA Supplement Vancomycin - pharmacology Yeast |
| title | Antimicrobial Activities of Fidaxomicin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T07%3A39%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20Activities%20of%20Fidaxomicin&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Goldstein,%20Ellie%20J.%20C.&rft.date=2012-08-01&rft.volume=55&rft.issue=suppl_2&rft.spage=S143&rft.epage=S148&rft.pages=S143-S148&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cis339&rft_dat=%3Cjstor_pubme%3E23249805%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026927985&rft_id=info:pmid/22752863&rft_jstor_id=23249805&rfr_iscdi=true |